1.Frehiwot N, Mizan K, Seble M, Fethia K, Tekalign M, Zelalem T: National guidelines for comprehensive HIV prevention, care and treatment. Addis Ababa: Ministry of Health 2014.
2.Federal Ministry of Health of Ethiopia: Implementation Guideline for TB/HIV Collaborative Activities in Ethiopia available at http://www.who.int/hiv/pub/guidelines/ethiopia.pdf. In.; December 2007.
3.Lawn SD, Meintjes G, McIlleron H, Harries AD, Wood R: Management of HIV-associated tuberculosis in resource-limited settings: a state-of-the-art review. BMC medicine 2013, 11(1):253.
4.WHO: HIV associatd tuberculosis achievement in2015. In.: World Health Organization; October 2016.
5.Beauté J, Dara M, Colombani Pd, Ehsani S, Gozalov O, Hovanesyan A, Ködmön C, Molnarova B, Boom M, van der Werf M: Tuberculosis surveillance and monitoring in Europe 2017. Tuberculosis surveillance and monitoring in Europe 2017 2017.
6.GLOBAL TUBERCULOSIS REPORT 2016: Country Profiles for 30 high-burden countries; 20 high TB burden countries based on absolute number of incident cases 10 high TB burden countries based on severity of disease burden(incidence per capita),
2015.
7.GLOBAL TUBERCULOSIS REPORT: GLOBAL TUBERCULOSIS REPORT 2016 available https://reliefweb.int/report/world/global-tuberculosis-report–2016. 2016.
8.Corbett EL, Marston B, Churchyard GJ, De Cock KM: Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment. The Lancet 2006, 367(9514):926–937.
9.Gao J, Zheng P, Fu H: Prevalence of TB/HIV co-infection in countries except China: a systematic review and meta-analysis. PLoS One 2013, 8(5):e64915.
10.Manosuthi W, Wiboonchutikul S, Sungkanuparph S: Integrated therapy for HIV and tuberculosis. AIDS Res Ther 2016, 13(1):22.
11.Muthamia OG, Chege PM: Determinants of Adherence to Anti Retroviral Therapy among Adults Living with HIV in Urban Low Income Settings: A Case of Kayole Division in Nairobi County, Kenya. survival 2011, 10:11.
12.Lemos LdA, Feijão AR, Gir E, Galvão MTG: Quality of life aspects of patients with HIV/tuberculosis co-infection. Acta Paulista de Enfermagem 2012, 25(SPE1):41–47.
13.Karambu S, Matiru V, Kiptoo M, Oundo J: Characterization and factors associated with diarrhoeal diseases caused by enteric bacterial pathogens among children aged five years and below attending Igembe District Hospital, Kenya. The Pan African medical journal 2013, 16:37.
14.Karambu S, Matiru V, Kiptoo M, Oundo J: Characterization and factors associated with diarrhoeal diseases caused by enteric bacterial pathogens among children aged five years and below attending Igembe District Hospital, Kenya. Pan African Medical Journal 2014, 16(1).
15.Alemu YM, Awoke W, Wilder-Smith A: Determinants for tuberculosis in HIV-infected adults in Northwest Ethiopia: a multicentre case–control study. BMJ open 2016, 6(4):e009058.
16.Assebe LF, Reda HL, Wubeneh AD, Lerebo WT, Lambert SM: The effect of isoniazid preventive therapy on incidence of tuberculosis among HIV-infected clients under pre-ART care, Jimma, Ethiopia: a retrospective cohort study. BMC public health 2015, 15(1):346.
17.Dowdy DW, Golub JE, Saraceni V, Moulton LH, Cavalcante SC, Cohn S, Pacheco AG, Chaisson RE, Durovni B: Impact of isoniazid preventive therapy for HIV-infected adults in Rio de Janeiro, Brazil: an epidemiological model. Journal of acquired immune deficiency syndromes (1999) 2014, 66(5):552.
18.Organization WH: The Use of Co-Trimoxazole Prophylaxis for HIV-Related Infections Among Adults, Adolescents and Children. In.: Geneva: WHO Press; 2013.
19.Sterling TR, Lau B, Zhang J, Freeman A, Bosch RJ, Brooks JT, Deeks SG, French A, Gange S, Gebo KA: Risk factors for tuberculosis after highly active antiretroviral therapy initiation in the United States and Canada: implications for tuberculosis screening. J Infect Dis 2011, 204(6):893–901.
20.Alene KA, Nega A, Taye BW: Incidence and predictors of tuberculosis among adult people living with human immunodeficiency virus at the University of Gondar Referral Hospital, Northwest Ethiopia. BMC Infect Dis 2013, 13(1):292.
21.Dalbo M, Tamiso A: Incidence and Predictors of Tuberculosis among HIV/AIDS Infected Patients: A Five-Year Retrospective Follow-Up Study. Advances in Infectious Diseases 2016, 6(02):70.
22.Enju L, MAKUBI A, DRAIN P, SPIEGELMAN D, SANDO D, Nan L, CHALAMILLA G, SUDFELD CR, HERTZMARK E, FAWZI WW: Tuberculosis incidence rate and risk factors among HIV-infected adults with access to antiretroviral therapy in Tanzania. AIDS (London, England) 2015, 29(11):1391.
23.Habtamu Oljira1 MI: Determinants of Active Tuberculosis among HIV-Positive Adults Attending Clinical Care in Ambo general hospital and Gedo hospital, West Shoa Zone, Oromia, Ethiopia (unmatched case-controlstudy),. Journal of Medicine, Physiology and Biophysics August 2015, 33(ISSN):2422–8427.
24.Melkamu H, Seyoum B, Dessie Y: Determinants of tuberculosis infection among adult HIV positives attending clinical care in western Ethiopia: A case-control study. AIDS research and treatment 2013, 2013.
25.Federal Democratic Republic of Ethiopia Ministry of Health: National comprehensive Tuberculosis, Leprosy and TB/HIV training manual for Health Care Workers In. Edited by Ababa A; 2016.
26.Ministry of Health E: National Comprehensive HIV Care and Treatment Training for Health care Providers
June, 2014.
27.Saraceni V, Durovni B, Cavalcante SC, Cohn S, Pacheco AG, Moulton LH, Chaisson RE, Golub JE: Survival of HIV patients with tuberculosis started on simultaneous or deferred HAART in the THRio cohort, Rio de Janeiro, Brazil. Braz J Infect Dis 2014, 18(5):491–495.
28.Pathmanathan I, Dokubo EK, Shiraishi RW, Agolory SG, Auld AF, Onotu D, Odafe S, Dalhatu I, Abiri O, Debem HC: Incidence and predictors of tuberculosis among HIV-infected adults after initiation of antiretroviral therapy in Nigeria, 2004–2012. PLoS One 2017, 12(3):e0173309.
29.Ahmed A, Mekonnen D, Kindie M: Incidence and Predictors of Tuberculosis among Adult People Living with HIV/AIDS in Afar Public Health Facilities, Northeast Ethiopia. AIDS 2015, 1:3–10.
30.Lawn SD, Badri M, Wood R: Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. Aids 2005, 19(18):2109–2116.
31.Purohit V, Bora V, Ramdeo R, Rewari B: Immune reconstitution inflammatory syndrome after initiation of antiretroviral therapy for HIV. Journal, Indian Academy of Clinical Medicine 2010, 11(2).
32.Bonnet MM, Pinoges LL, Varaine FF, Oberhauser BB, DO O’Brien D, Kebede YY, Hewison CC, Zachariah RR, Ferradini LL: Tuberculosis after HAART initiation in HIV-positive patients from five countries with a high tuberculosis burden. Aids 2006, 20(9):1275–1279.
33.Kibret KT, Yalew AW, Belaineh BG, Asres MM: Determinant factors associated with occurrence of tuberculosis among adult people living with HIV after antiretroviral treatment initiation in Addis Ababa, Ethiopia: a case control study. PLoS One 2013, 8(5):e64488.
34.Mitku AA, Dessie ZG, Muluneh EK, Workie DL: Prevalence and associated factors of TB/HIV co-infection among HIV Infected patients in Amhara region, Ethiopia. Afr Health Sci 2016, 16(2):588–595.
35.Ethiopian Public Health Institute (EPHI): Report on National TB/HIV Sentinel Surveillance April 2010 - June 2015,available https://www.ephi.gov.et/images/pictures/Final_National_TB HIV_Sentinel_Surveillance__OCT_20_FE2015_(1)%20(1).pdf. In.; December 2015.